Announcement PDF ABN 16 165 160 841 ASX RELEASE 2 January 2024 Change of Director’s Interest Notice – Appendix 3Y: Dr Christopher Burns Appendix 3Y Change of Director’s Interest Notice for Dr. Christopher Burns is attached. This ASX announcement was approved and authorised for release by the Company Secretary of Amplia Therapeutics Limited. Investor Contact: Dr Chris Burns Chief Executive Officer chris@ampliatx.com Media Contact: H^CK Director, Haley Chartres haley@hck.digital +61 423 139 163 About Amplia Therapeutics Limited Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in fibrotic cancers such as pancreatic cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on Twitter (@ampliatx) and LinkedIn. Level 17, 350 Queen St, Melbourne VIC 3000 Email info@ampliatx.com www.ampliatx.com Appendix 3Y Change of Director’s Interest Notice Appendix 3Y Rule 3.19A.2 Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity Amplia Therapeutics Limited ABN 16 165 160 841 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Christopher John Burns Date of last notice 29 August 2023 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Direct Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. Date of change 31 December 2023 No. of securities held prior to change 2,527,798 Fully Paid Ordinary Shares 18,519 ATXO Listed Options Ex Price $0.28 Exp 31 Dec 2023 535,000 Unlisted Options Exercise Price A$0.26 Expiry Date 6 Sep 2025 2,500,000 Unlisted Options Exercise Price $0.135 Expiry Date 5 June 2028 Class ATXO Listed Options Ex Price $0.28 Exp 31 Dec 2023 Number acquired Nil Number disposed 18,519 Value/Consideration Nil – Options expired unexercised Note: If consideration is non-cash, provide details and estimated valuation + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice No. of securities held after change 2,527,798 Fully Paid Ordinary Shares 535,000 Unlisted Options Exercise Price A$0.26 Expiry Date 6 Sep 2025 2,500,000 Unlisted Options Exercise Price $0.135 Expiry Date 5 June 2028 Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back ATXO Listed Options Ex Price $0.28 Exp 31 Dec 2023 – options expired unexercised. Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract Nil Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change Part 3 – +Closed period Were the interests in the securities or contracts detailed above No traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to proceed during this period? If prior written clearance was provided, on what date was this provided? 2 January 2024 + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011